ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
57 announcements with these filters
Biocon's June 2026 presentation highlights its transformation into an integrated biopharma leader following the Viatris acquisition. FY26 revenue reached $1,924M (₹16,927 Cr) with a 22% EBITDA margin.
Biocon Limited has initiated a postal ballot for shareholder approval of a preferential equity share issuance. This corporate action seeks authorization for consideration other than cash.
Biocon issued a corrigendum to its May 07 postal ballot notice regarding a ₹330.73 Crore preferential issue. It revises floor price, issue price, and allotment details.
Biocon Q4 FY26 reported 10% YoY revenue growth (ex-lenalidomide) with integration of biosimilars/generics complete. Focus shifts to execution and deleveraging.
Biocon Pharma received Health Canada approval for Micafungin for Injection, USP. This milestone strengthens the company's integrated biosimilars and generics portfolio in Canada.
Biocon Limited issued a postal ballot notice for multiple resolutions, including a ₹330.73 Crore preferential share issuance. Shareholders will vote electronically between May and June 2026.
Biocon Q3FY26 reports 9% operating revenue growth at Rs 4,173 Cr and 475% increase in Net Profit to Rs 144 Cr, driven by Biosimilars and Generics momentum.
Biocon Limited announced a significant leadership restructuring, appointing several independent directors and senior management personnel. The board additions include global pharmaceutical and technology leaders.
Biocon Limited recommended a final dividend of Rs. 0.1 per equity share for FY26. The record date is set for July 3, 2026.
Biocon Limited will acquire 1.06 crore equity shares in Biocon Biologics via CCD conversion worth ₹473.40 Crore. The move aims to simplify its corporate structure.
Biocon will acquire a minority stake in Biocon Biologics for ₹330.73 Crore via share-swap. The deal consolidates BBL as a wholly owned subsidiary by June 2026.
Biocon reported FY26 revenue of ₹16,927 Cr (+13% YoY adjusted). Transitioning from investment phase to execution, focusing on margin expansion and deleveraging across Biosimilars, Generics, and CRDMO.
Biocon Limited released Monitoring Agency Reports confirming zero deviation in utilizing ₹8,650 Crore raised via QIPs. The Audit Committee reviewed these reports on May 07, 2026.
Biocon Ltd reported Q4FY26 total income of ₹4,569 Crore and EBITDA of ₹1,073 Crore. Performance was driven by biosimilars and generics growth amid business integration.
Biocon Ltd reported revenue from operations of ₹604.7 Cr (-6.1% YoY) and net profit of ₹51 Cr (+140.6% YoY) for Q4 FY26.
Biocon Limited reported its audited financial results for the year ended March 31, 2026. The board also recommended a final dividend of Rs. 0.50 per share.
Biocon Ltd clarified to exchanges that Ms. Kiran Mazumdar-Shaw remains Executive Chairperson and is not stepping down. The company denied reports of impending management or succession changes following media speculation and stock price movement on May 06, 2026. Management reiterated that all material information is disclosed per SEBI regulations.
Biocon Limited has scheduled a board meeting for May 7, 2026, to consider a proposal for fundraising via a preferential issue. The trading window for the company's securities remains closed from April 1, 2026, until May 9, 2026, as per insider trading regulations.
Biocon Limited's Board will meet on May 07, 2026, to consider a preferential allotment of equity shares. This issuance is intended to fund the acquisition of equity shares in its material subsidiary, Biocon Biologics Limited, for consideration other than cash. The transaction is subject to shareholder approval via postal ballot.
Biocon Limited announced that the U.S. FDA completed a Pre-License Inspection at its Bengaluru biosimilars site. The inspection concluded with five procedural observations. The company plans to submit a corrective action plan and does not expect any impact on data integrity or quality oversight.
Biocon Limited confirmed the full utilization of ₹200 Crore raised through Commercial Papers for the quarter ended March 31, 2026. The funds were deployed for subsidiary equity acquisition and debt redemption. The company reported no deviation in fund usage and fulfilled all payment obligations by January 30, 2026.
Biocon Limited has scheduled a Board Meeting on May 7, 2026, to consider audited standalone and consolidated financial results for the year ended March 31, 2026. The board will also consider a recommendation for a final dividend. The trading window for designated persons remains closed until May 9, 2026.
Biocon Ltd will hold a Board Meeting on May 07, 2026, to approve audited financial results for the fiscal year ended March 31, 2026, and recommend a dividend. An earnings conference call is scheduled for May 08, 2026. The trading window for designated persons remains closed until May 09, 2026.
Biocon Limited received Health Canada approval for its biosimilars Bosaya and Vevzuo, marking its entry into the Canadian denosumab market. The approval targets osteoporosis and cancer-related bone conditions, potentially benefiting over 2 million patients. This milestone strengthens Biocon's global biosimilars portfolio across immunology and oncology.
Biocon Pharma, a subsidiary of Biocon Limited, received U.S. FDA approval for Dapagliflozin Tablets (5 mg and 10 mg) for treating type 2 diabetes. The product will be manufactured at Biocon's FDA-approved facilities. This approval strengthens Biocon's global diabetes portfolio, covering oral solids, biosimilar insulins, and GLP-1 peptides.
Biocon Limited submitted a compliance certificate under SEBI Regulations for the quarter ended March 31, 2026. The certificate confirms that security certificates received for dematerialization were processed and mutilated by the Registrar, KFin Technologies Limited. This is a routine quarterly disclosure with no direct financial impact.
Biocon Limited has commercially launched Bosaya and Aukelso, its interchangeable denosumab biosimilars, in the United States. These products target the $5 billion U.S. market for osteoporosis and bone metastasis treatments. This strategic expansion strengthens Biocon's global biosimilars portfolio and provides affordable treatment options for over 10 million patients.